Nutriband Inc. Announces 25% Preferred Stock Dividend Linked to AVERSA Fentanyl Approval - FAQ
Summary
Nutriband Inc. (NASDAQ: NTRB) has declared a 25% preferred stock dividend, with conversion to common shares contingent upon FDA approval of its AVERSA Fentanyl product, highlighting the company's commitment to shareholder value and progress towards commercialization.
What is the significance of Nutriband Inc.’s announced 25% preferred stock dividend?
The 25% preferred stock dividend signifies Nutriband Inc.’s commitment to enhancing shareholder value and reflects the company’s progress towards the commercialization of its AVERSA Fentanyl product, pending FDA approval.
How does the preferred stock dividend work?
For every four common shares held as of July 25, 2025, shareholders will receive one preferred share, which can convert to one common share upon FDA approval of AVERSA Fentanyl or be eligible for annual cash dividends at the Board’s discretion.
When will the preferred shares be distributed?
The preferred shares are set to be distributed on August 5, 2025, to shareholders of record as of July 25, 2025.
What is AVERSA Fentanyl?
AVERSA Fentanyl is Nutriband’s lead product under development, an abuse-deterrent fentanyl patch incorporating AVERSA technology to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Who is affected by this announcement?
Current shareholders of Nutriband Inc. (NASDAQ: NTRB) as of July 25, 2025, are directly affected, as they will be eligible to receive the preferred stock dividend.
What happens if the FDA does not approve AVERSA Fentanyl?
If the FDA does not approve AVERSA Fentanyl, the preferred shares will not convert to common shares but may be eligible for annual cash dividends from company profits at the Board’s discretion.
Where can I find more information about Nutriband Inc.?
More information about Nutriband Inc. can be found on their official website at www.Nutriband.com or in the company’s newsroom at https://ibn.fm/NTRB.
What is the purpose of the AVERSA technology?
AVERSA technology is designed to be incorporated into transdermal patches to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, enhancing patient safety and drug efficacy.
How does this announcement reflect on Nutriband’s future?
This announcement reflects Nutriband’s strategic focus on advancing its product pipeline, particularly AVERSA Fentanyl, and its commitment to delivering value to shareholders through innovative pharmaceutical solutions.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 99424